HOME | COUNTRIES | CITIES | COMPANIES | SPORTS | CARS
news videos images websites
 


Gilead Sciences Company News

Wed, 12 Oct 2016 00:15:30 GMT
Is there Inherent Value in Gilead Sciences, Inc. (NASDAQ:GILD) Shares? Analyst's Take  -  Engelwood Daily
Sell-side Street analysts covering Gilead Sciences, Inc. (NASDAQ:GILD) presently have an average rating of 1.95 on company shares. This consensus rating is using 14 analysts polled by Zacks Research. On a numerical scale from 1 to 5, a rating of 1 or 2 ...
Tue, 11 Oct 2016 21:52:46 GMT

Gilead Sciences Inc. (GILD) Stake Reduced by North Point Portfolio Managers Corp OH  -  The Cerbat Gem
Gilead Sciences logo North Point Portfolio Managers Corp OH decreased its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 2.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned ...
Tue, 11 Oct 2016 21:52:46 GMT

Bartlett & Co. LLC Has $27942000 Stake in Gilead Sciences Inc. (GILD)  -  The Cerbat Gem
Gilead Sciences logo Bartlett & Co. LLC boosted its position in Gilead Sciences Inc. (NASDAQ:GILD) by 1.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 334,952 ...
Tue, 11 Oct 2016 21:52:25 GMT
Calamos Advisors LLC Raises Stake in Gilead Sciences Inc. (GILD)  -  BBNS
Gilead Sciences logo Calamos Advisors LLC raised its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 32.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 723,334 shares ...
Tue, 11 Oct 2016 21:52:25 GMT
Underhill Investment Management LLC Purchases 17850 Shares of Gilead Sciences Inc. (GILD)  -  BBNS
Gilead Sciences logo Underhill Investment Management LLC boosted its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 15.8% during the second quarter, according to its most recent filing with the SEC. The firm owned 130,750 shares of the ...
Tue, 11 Oct 2016 17:54:54 GMT

Gilead Sciences, Inc. (GILD) Options Traders Eye an End-of-Week Rebound  -  Schaeffers Research (blog)
Gilead Sciences, Inc. (NASDAQ:GILD) is fresh off a more than two-year low of $73.90, and was last seen sitting on a 2% loss at $73.93. Amid these technical woes, the drugmaker's options volume is slightly accelerated, running at 1.3 times the usual ...
Tue, 11 Oct 2016 16:35:03 GMT

Allergan Challenges Intercept With Tobira NASH Drug  -  Investor's Business Daily
Allergan (AGN) is taking on Gilead Sciences (GILD) and Intercept Pharmaceuticals (ICPT) with its acquisition of Tobira Therapeutics (TBRA), but Mizuho analyst Irina Koffler likes the deal, saying a key Tobira drug has "a solid chance of approval ...
Tue, 11 Oct 2016 16:34:41 GMT
Turning Bullish On Gilead - Bezek's Daily Briefing  -  Seeking Alpha
With the stock at $120, just a couple bucks short of its all-time high, I called "sell" on Gilead in a contest-winning article that generated more than 300 comments, mostly negative. That's no surprise, in it, I specifically warned that many people ...
Tue, 11 Oct 2016 15:19:48 GMT
Stocks in News: Ocular Therapeutix, Inc. (NASDAQ:OCUL), Gilead Sciences Inc. (NASDAQ:GILD), Chubb Limited ...  -  Benchmark Monitor
On 10 October Ocular Therapeutix, Inc. (NASDAQ:OCUL) traded 415385 shares as and was closed at $6.81. Company is -60.73% away from its one year high and is moving 68.56% ahead of its one year low. Stock monthly performance is recorded as 0.44% ...
Tue, 11 Oct 2016 14:48:39 GMT
Pro ad report: All the data on journal spending in 1H 2016  -  Medical Marketing and Media
Professional advertising spending behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. But cancer drugs once again were the hottest category. Check out ...